[A04] Goat Anti-Human Apolipoprotein AII Polyclonal Antibody, Academy Bio-medical Company, Inc.

[A04] Goat Anti-Human Apolipoprotein AII Polyclonal Antibody


Academy Bio-Medical Company, Inc.

  • $155.00

Host Species: Goat
Concentration: 1 mg/ml (OD 1.35 / 280 nm)
Antigen: Human Apolipoprotein AII
Purification: Affinity purified
Buffer: 75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity Specifically binds to human apo AII. Dilution for immunoblot and ELISA range: 1,000 to 40,000.
Use: The antibody can be used for detection of apo AII in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage: -20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.


*These products are for research or manufacturing use only, not for use in human therapeutic ordiagnostic applications.


Apo AII comprises 25% of HDL. It exists in human plasma as a dimer of 2 identical chains of 77 amino acid residues, joined by disulfide. The molecular weight is reported to be 8.7 kDa for a single chain (Brewer et al., 1972).

Studies on mouse reported that apo AII may be proatherogenic (Warden et al., 1993); however, case-control study in the large European Prospective Investigation demonstrated that plasma Apo AII concentrations were strongly inversely correlated with CHD events (Birjmohun et al., 2007).

Birjmohun, R. S., G. M. Dallinga-Thie, J. A. Kuivenhoven, E. S.g. Stroes, J. D. Otvos, N. J. Wareham, R. Luben, J. J.p. Kastelein, K.-T. Khaw, and S. M. Boekholdt. "Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease." Circulation 116 (2007): 2029-035.

Brewer, H. B., S. E. Lux, R. Ronan, and K. M. John. "Amino Acid Sequence of Human ApoLp-Gln-II (apoA-II), an Apolipoprotein Isolated from the High-Density Lipoprotein Complex." Proceedings of the National Academy of Sciences 69.5 (1972): 1304-308.

Warden, C., C. Hedrick, J. Qiao, L. Castellani, and A. Lusis. "Atherosclerosis in Transgenic Mice Overexpressing Apolipoprotein A-II." Science 261 (1993): 469-72.



[A04][A05][A06] 2020 Lee, An-Sheng; Wang, Yu-Chen; Chang, Shih-Sheng; Lo, Ping-Hang; Chang, Chia-Ming; Lu, Jonathan et al. (2020): Detection of a High Ratio of Soluble to Membrane-Bound LOX-1 in Aspirated Coronary Thrombi From Patients With ST-Segment-Elevation Myocardial Infarction. Journal of the American Heart Association 9 (2), e014008. DOI: 10.1161/JAHA.119.014008.
[A04][A05][A06] 2017 Gillard, Baiba K.; Bassett, G. Randall; Gotto, Antonio M.; Rosales, Corina; Pownall, Henry J. (2017): Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester. In J. Biol. Chem. 292 (21), pp. 8864–8873. DOI: 10.1074/jbc.M117.781963.
[A04][A05][A06] 2017 Ikeda, Toru; Shinohata, Ryoko; Murakami, Masaaki; Hina, Kazuyoshi; Kamikawa, Shigeshi; Hirohata, Satoshi et al. (2017): A rapid and precise method for measuring plasma apoE-rich HDL using polyethylene glycol and cation-exchange chromatography: a pilot study on the clinical significance of apoE-rich HDL measurements. In Clinica Chimica Acta; International Journal of Clinical Chemistry 465, pp. 112–118. DOI: 10.1016/j.cca.2016.12.016.
[A04][A05][A06] 2016 Azizkhanian, Ida; Trenchevska, Olgica; Bashawri, Yara; Hu, Jiaqi; Koska, Juraj; Reaven, Peter D. et al. (2016): Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. In Journal of Clinical Lipidology 10 (4), pp. 808–815. DOI: 10.1016/j.jacl.2016.03.001.
[A04][A05][A06] 2015 Kameda, Takahiro; Ohkawa, Ryunosuke; Yano, Kouji; Usami, Yoko; Miyazaki, Akari; Matsuda, Kazuyuki et al. (2015): Effects of Myeloperoxidase-Induced Oxidation on Antiatherogenic Functions of High-Density Lipoprotein. In Journal of Lipids 2015 (9), pp. 1–8. DOI: 10.1155/2015/592594.
[A04][A05][A06] 2014 Miyazaki, Akari; Sagae, Nozomi; Usami, Yoko; Sato, Megumi; Kameda, Takahiro; Yoshimoto, Akira et al. (2014): N-homocysteinylation of apolipoprotein A-I impairs the protein’s antioxidant ability but not its cholesterol efflux capacity. In Biological Chemistry 395 (6). DOI: 10.1515/hsz-2013-0262.
[A04][A05][A06] 2012 Kameda, Takahiro; Usami, Yoko; Shimada, Saki; Haraguchi, Go; Matsuda, Kazuyuki; Sugano, Mitsutoshi et al. (2012): Determination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoprotein. In Annals of Clinical and Laboratory Science 42 (4), pp. 384–391.
[A04][A05][A06] 2011 Holmberg, R.; Refai, E.; Hoog, A.; Crooke, R. M.; Graham, M.; Olivecrona, G. et al. (2011): Lowering apolipoprotein CIII delays onset of type 1 diabetes. In J. Biol. Chem. 108 (26), pp. 10685–10689. DOI: 10.1073/pnas.1019553108.
[A04][A05][A06] 2011 Sakamoto, Haruhiko; Wu, Bin; Nagai, Yumiko; Tanaka, Sumiko; Onodera, Masayuki; Ogawa, Takafumi; Ueno, Masaki (2011): Platelet high-density lipoprotein activates transferrin-derived phagocytosis activators, MAPPs, following thrombin digestion. In Platelets 22 (5), pp. 371–379. DOI: 10.3109/09537104.2010.533797.
[A04][A05][A06] 2008 Deng, Ting; Ji, Wei; Lian, Ji-Hong; Guo, Lei; Hu, Wei-Rong; Qian, Ming; Gong, Bang-qiang (2008): Identifying Natural Derived Upregulators of Human ApoA-I Expression via a Cell-Based Drug Screening System. In Pharmaceutical Biology 46 (9), pp. 610–615. DOI: 10.1080/13880200802179584.
[A04][A05][A06] 2006 Guo, Lei; Hu, Wei-Rong; Lian, Ji-Hong; Ji, Wei; Deng, Ting; Qian, Ming; Gong, Bang-qiang (2006): Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. In European Journal of Pharmacology 551 (1-3), pp. 80–86. DOI: 10.1016/j.ejphar.2006.08.048.
[A04][A05][A06] 2006 Thompson, Patricia A.; Kitchens, Richard L. (2006): Native high-density lipoprotein augments monocyte responses to lipopolysaccharide (LPS) by suppressing the inhibitory activity of LPS-binding protein. In J.I. 177 (7), pp. 4880–4887. DOI: 10.4049/jimmunol.177.7.4880.
[A04][A05][A06] 2005 Nedelkov, Dobrin; Kiernan, Urban A.; Niederkofler, Eric E.; Tubbs, Kemmons A.; Nelson, Randall W. (2005): Investigating diversity in human plasma proteins. In Proc Natl Acad Sci USA 102 (31), pp. 10852–10857. DOI: 10.1073/pnas.0500426102.
[A04][A05][A06] 2004 Ogasawara, Ken; Mashiba, Shinichi; Wada, Youichiro; Sahara, Makoto; Uchida, Kazuo; Aizawa, Tadanori; Kodama, Tatsuhiko (2004): A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. In Atherosclerosis 174 (2), pp. 349–356. DOI: 10.1016/j.atherosclerosis.2004.01.030.
[A04][A05][A06] 2003 Niederkofler, Eric E.; Tubbs, Kemmons A.; Kiernan, Urban A.; Nedelkov, Dobrin; Nelson, Randall W. (2003): Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. In J. Lipid Res. 44 (3), pp. 630–639. DOI: 10.1194/jlr.D200034-JLR200.
[A04][A05][A06] 2001 Yuhanna, I. S.; Zhu, Y.; Cox, B. E.; Hahner, L. D.; Osborne-Lawrence, S.; Lu, P. et al. (2001): High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. In Nature Medicine 7 (7), pp. 853–857. DOI: 10.1038/89986.

We Also Recommend